Patent ID: 7012095

Claim:
A pharmaceutical composition suitable for oral, intravenous, intraperitoneal, subcutaneous, intramuscular, nasal, intrapulmonary, intrathecal, or rectal administration, comprising a compound of Formula I, or a salt, solvate or hydrate thereof: wherein R 1 and R 2 are each independently selected from H, OH, C 1-6 alkyl, C 1-6 alkoxy, NH 2 , NH—C 1-6 alkyl, N(C 1-6 alkyl)(C 1-6 alkyl), SH, S—C 1-6 alkyl, O—Si(C 1-6 alkyl)(C 1-6 alkyl)(C 1-6 alkyl), NO 2 , CF 3 , OCF 3 and halo; R 3 is selected from H, OH, C 1-6 alkyl, C 1-6 alkoxy, NH 2 , NH—C 1-6 alkyl, N(C 1-6 alkyl)(C 1-6 alkyl), SH, S—C 1-6 alkyl, O—Si(C 1-6 alkyl)(C 1-6 alkyl)(C 1-6 alkyl), NO 2 , halo and CH 2 —S—(CH 2 ) n Ar; R 4 is selected from C(X)R 5 , SO 3 Ar, NH 2 , NH—C 1-6 alkyl, N(C 1-6 alkyl)(C 1-6 alkyl), P(O)(OH) 2 , and C(NH 2 )═C(CN) 2 ; X is selected from O, S, NH and N—C 1-6 alkyl; R 5 is selected from NH 2 , NH(CH 2 ) p Ar, NH(CH 2 ) p OH, (CH 2 ) p OC 1-6 alkyl, C 1-6 alkyl, NHNH 2 , NHC(O)NH 2 , NHC(O)C 1-6 alkoxy, N-morpholino and N-pyrrolidino; and Ar is an aromatic group, unsubstituted or substituted with 1–4 substituents, independently selected from OH, C 1-6 alkyl, C 1-6 alkoxy, NH 2 , NH—C 1-6 alkyl, N(C 1-6 alkyl)(C 1-6 alkyl), SH, S—C 1-6 alkyl, NO 2 , CF 3 , OCF 3 and halo; n is 0 to 4; and p is 1–4, in admixture with a pharmaceutically acceptable diluent or carrier.